SINOPHARM (01099) announced its interim results, with a net profit attributable to shareholders of 3.404 billion yuan, a year-on-year decrease of 1.79%.

SINOPHARM (01099) announced its mid-year results for 2026, reporting revenue of 282.8 billion yuan, a year-on-year decrease of 1.13%; profit attributable to the parent company was 3.404 billion yuan, a year-on-year decrease of 1.79%; basic earnings per share were 1.09 yuan. The announcement stated that the decrease in revenue was due to the decline in income from the groups pharmaceutical distribution and medical device distribution businesses. During the reporting period, the groups pharmaceutical distribution revenue was 215.496 billion yuan, a decrease of 1.39% compared to 218.527 billion yuan for the six months ending June 30, 2025, accounting for 72.98% of the groups total revenue. The decline was primarily influenced by multiple factors including volume-based procurement, price governance of red and yellow label products, and medical insurance regulation. During the reporting period, the groups medical device distribution revenue was 56.854 billion yuan, a decrease of 0.35% compared to 57.053 billion yuan for the six months ending June 30, 2025, accounting for 19.25% of the groups total revenue. The decline was mainly due to the impact of the implementation of centralized procurement policies for large equipment in public medical institutions, leading to a decrease in sales revenue from medical instruments and equipment.